
Sign up to save your podcasts
Or


Send us a text
If our visual scoring is still based on gut feeling, how do we scale precision?
In this week’s DigiPath Digest, I explored four new AI-focused papers that could reshape how we diagnose prostate, bladder, gastroesophageal, and endocrine cancers.
From automated IHC scoring to predicting urethral recurrence post-cystectomy, these studies highlight the growing value—and responsibility—of integrating AI into our pathology workflows.
And yes, I also reveal where to get my histology-inspired earrings 😉
Episode Highlights
[06:00] Muse Vet Platform launch + STP talk
[11:00] Tools I use: Perplexity, RAG, ChatGPT, and AI citation traps
[14:00] AI’s promise—and its pitfalls
Paper 1: IHC Scoring in GEC (Caputo et al.)
Manual PD-L1 and HER2 scoring is subjective. This study shows AI can standardize and improve accuracy using digital tools for GEC.
[20:00] AI reduces visual bias
[23:00] Potential to replace expensive assays
Paper 2: ASAP in Prostate Biopsies
Page Prostate AI matched final diagnoses 85% of the time—more than human reviewers.
[24:00] ASAP = gray zone diagnosis
[27:00] AI matched final calls more often than humans
Paper 3: Recurrence Prediction Post-Cystectomy
Chinese study developed a recurrence model using ML on clinical data. AUC: 0.86 (train), 0.77 (test).
[30:00] Risk factors: CIS, bladder neck involvement
[32:00] SHAP explained model insights
Paper 4: Reticulin Framework in Endocrine Pathology
Reticulin stains are cheap but powerful. This paper calls for AI to take notice.
[36:00] Reticulin separates benign from malignant
[40:00] Let’s train AI on these patterns
📚 Resource from this Episode
AI is already enhancing diagnostic precision—we just need to guide its use responsibly. From special stains to advanced models, this episode covers where we're headed next.
Support the show
Get the "Digital Pathology 101" FREE E-book and join us!
By Aleksandra Zuraw, DVM, PhD5
77 ratings
Send us a text
If our visual scoring is still based on gut feeling, how do we scale precision?
In this week’s DigiPath Digest, I explored four new AI-focused papers that could reshape how we diagnose prostate, bladder, gastroesophageal, and endocrine cancers.
From automated IHC scoring to predicting urethral recurrence post-cystectomy, these studies highlight the growing value—and responsibility—of integrating AI into our pathology workflows.
And yes, I also reveal where to get my histology-inspired earrings 😉
Episode Highlights
[06:00] Muse Vet Platform launch + STP talk
[11:00] Tools I use: Perplexity, RAG, ChatGPT, and AI citation traps
[14:00] AI’s promise—and its pitfalls
Paper 1: IHC Scoring in GEC (Caputo et al.)
Manual PD-L1 and HER2 scoring is subjective. This study shows AI can standardize and improve accuracy using digital tools for GEC.
[20:00] AI reduces visual bias
[23:00] Potential to replace expensive assays
Paper 2: ASAP in Prostate Biopsies
Page Prostate AI matched final diagnoses 85% of the time—more than human reviewers.
[24:00] ASAP = gray zone diagnosis
[27:00] AI matched final calls more often than humans
Paper 3: Recurrence Prediction Post-Cystectomy
Chinese study developed a recurrence model using ML on clinical data. AUC: 0.86 (train), 0.77 (test).
[30:00] Risk factors: CIS, bladder neck involvement
[32:00] SHAP explained model insights
Paper 4: Reticulin Framework in Endocrine Pathology
Reticulin stains are cheap but powerful. This paper calls for AI to take notice.
[36:00] Reticulin separates benign from malignant
[40:00] Let’s train AI on these patterns
📚 Resource from this Episode
AI is already enhancing diagnostic precision—we just need to guide its use responsibly. From special stains to advanced models, this episode covers where we're headed next.
Support the show
Get the "Digital Pathology 101" FREE E-book and join us!

229,245 Listeners

323 Listeners

126 Listeners

499 Listeners

310 Listeners

302 Listeners

499 Listeners

125 Listeners

320 Listeners

20 Listeners

93 Listeners

368 Listeners

16 Listeners

148 Listeners

4 Listeners